|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003286,
umls-concept:C0017638,
umls-concept:C0022417,
umls-concept:C0034897,
umls-concept:C0076080,
umls-concept:C0205618,
umls-concept:C0282460,
umls-concept:C0338344,
umls-concept:C0439849,
umls-concept:C0449438,
umls-concept:C0600688
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2006-9-26
|
|
pubmed:abstractText |
Since anaplastic gliomas (AG) depend on matrix metalloproteinases for tumor cell invasion and angiogenesis, we undertook this phase II study to evaluate the matrix metalloproteinase inhibitor marimastat (MT), combined with the alkylator temozolomide (TMZ) in patients with recurrent AG, looking for improved outcomes.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0167-594X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
80
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
83-90
|
|
pubmed:meshHeading |
pubmed-meshheading:16639492-Anticonvulsants,
pubmed-meshheading:16639492-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16639492-Brain Neoplasms,
pubmed-meshheading:16639492-Cytochrome P-450 Enzyme System,
pubmed-meshheading:16639492-Dacarbazine,
pubmed-meshheading:16639492-Disease-Free Survival,
pubmed-meshheading:16639492-Enzyme Inhibitors,
pubmed-meshheading:16639492-Glioma,
pubmed-meshheading:16639492-Humans,
pubmed-meshheading:16639492-Hydroxamic Acids,
pubmed-meshheading:16639492-Joint Diseases,
pubmed-meshheading:16639492-Joints,
pubmed-meshheading:16639492-Neoplasm Recurrence, Local,
pubmed-meshheading:16639492-Survival Analysis,
pubmed-meshheading:16639492-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.
|
|
pubmed:affiliation |
Department of Neuro-Oncology, Unit #431, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. mgroves@mdanderson.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
